Intersect ENT Company Profile (NASDAQ:XENT)

About Intersect ENT

Intersect ENT, Inc. is a commercial stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. It has developed a drug releasing bio-absorbable implant technology that enables targeted and sustained release of therapeutic agents. Its commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. It is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. Its steroid releasing implants are the drug releasing implants for chronic sinusitis sufferers. The PROPEL mini implant is a smaller version of PROPEL and is manufactured from the same bio-absorbable polymer fiber and with the same drug releasing coating and other design characteristics. It also developing NOVA, a steroid releasing implant.

Industry, Sector and Symbol:

Sector: Medical
Industry: Medical Appliances & Equipment
Sub-Industry: N/A
Exchange: NASDAQ
Symbol: XENT
CUSIP:

Key Metrics:

Previous Close: $15.61
50 Day Moving Average: $15.25
200 Day Moving Average: $15.52
52-Week Range: $11.88 - $23.13
Trailing P/E Ratio: N/A
Foreward P/E Ratio: -23.30
P/E Growth: 0.12
Market Cap: $444.17M
Outstanding Shares: 28,454,000
Beta: 1.01

Profitability:

Net Margins: -42.97%
Return on Equity: -23.31%
Return on Assets: -21.08%

Debt:

Current Ratio: 12.07%
Quick Ratio: 11.52%

Additional Links:

Companies Related to Intersect ENT:

Consensus Ratings for Intersect ENT (NASDAQ:XENT) (?)

Ratings Breakdown:	1 Hold Rating, 8 Buy Ratings
Consensus Rating:	Buy (Score: 2.89)
Consensus Price Target:	$24.78 (58.73% upside)

Analysts' Ratings History for Intersect ENT (NASDAQ:XENT)

Show:

Date	Firm	Action	Rating	Price Target
9/23/2016	Wedbush	Reiterated Rating	Outperform	$25.00
8/26/2016	Piper Jaffray Cos.	Reiterated Rating	Overweight	$21.00
8/4/2016	Canaccord Genuity	Reiterated Rating	Buy	$20.00
8/4/2016	BTIG Research	Reiterated Rating	Hold	$14.00
3/29/2016	Northland Securities	Initiated Coverage	Outperform	$26.00
3/24/2016	Leerink Swann	Reiterated Rating	Buy
3/24/2016	Cantor Fitzgerald	Reiterated Rating	Buy	$29.00
12/18/2015	Bank of America Corp.	Initiated Coverage	Buy	$26.00
10/2/2015	Sterne Agee CRT	Reiterated Rating	Buy	$37.00
6/4/2015	JPMorgan Chase & Co.	Boost Price Target	Overweight	$28.00 -> $37.00
4/8/2015	CRT Capital	Initiated Coverage	Buy	$32.00
12/11/2014	William Blair	Initiated Coverage	Outperform

(Data available from 9/29/2014 forward)

Earnings History for Intersect ENT (NASDAQ:XENT)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/2/2016
8/2/2016	Q216	($0.26)	($0.21)	$18.91 million	$19.30 million	View	N/A
5/5/2016	Q116	($0.29)	($0.29)	$16.92 million	$16.69 million	View	N/A
2/23/2016	Q415	($0.25)	($0.20)	$18.36 million	$18.80 million	View	Listen
11/4/2015	Q315	($0.29)	($0.35)	$14.80 million	$14.20 million	View	N/A
8/5/2015	Q215	($0.26)	($0.23)	$14.74 million	$15.20 million	View	N/A
5/6/2015	Q115	($0.33)	($0.23)	$13.00 million	$13.37 million	View	N/A
2/26/2015	Q414	($0.29)	($0.16)	$12.20 million	$13.40 million	View	N/A
11/5/2014	Q314	($0.35)	($0.32)	$8.20 million	$9.10 million	View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Intersect ENT (NASDAQ:XENT)

Current Year EPS Consensus Estimate: $-0.96 EPS
Next Year EPS Consensus Estimate: $-0.67 EPS

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2016	6	($0.31)	($0.14)	($0.27)
Q2 2016	5	($0.29)	($0.12)	($0.24)
Q3 2016	3	($0.32)	($0.25)	($0.27)
Q4 2016	3	($0.20)	($0.15)	($0.18)
Q1 2017	1	($0.25)	($0.25)	($0.25)
Q2 2017	1	($0.21)	($0.21)	($0.21)
Q3 2017	1	($0.28)	($0.28)	($0.28)
Q4 2017	1	($0.05)	($0.05)	($0.05)

(Data provided by Zacks Investment Research)

Dividend History for Intersect ENT (NASDAQ:XENT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Intersect ENT (NASDAQ:XENT)

Insider Ownership Percentage: 13.90%
Institutional Ownership Percentage: 77.80%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
9/7/2016	Amy Wolbeck	VP	Sell	28,664	$15.83	$453,751.12
9/6/2016	James Stambaugh	VP	Sell	4,000	$16.00	$64,000.00
8/3/2016	James Stambaugh	VP	Sell	3,977	$17.00	$67,609.00
7/18/2016	James Stambaugh	VP	Sell	5,000	$15.33	$76,650.00
6/13/2016	James Stambaugh	VP	Sell	500	$14.38	$7,190.00
5/16/2016	Kieran Gallahue	Director	Buy	8,000	$12.64	$101,120.00
4/27/2016	Amy Wolbeck	VP	Sell	2,000	$20.01	$40,020.00
4/20/2016	Richard E Kaufman	COO	Sell	3,603	$18.86	$67,952.58
4/18/2016	Lisa D Earnhardt	CEO	Sell	28,500	$18.69	$532,665.00
3/21/2016	Richard E Kaufman	COO	Sell	3,603	$16.51	$59,485.53
3/15/2016	Lisa D Earnhardt	CEO	Sell	9,000	$18.01	$162,090.00
3/14/2016	Frederic H Moll	Director	Sell	1,299	$18.53	$24,070.47
3/8/2016	Frederic H Moll	Director	Sell	601	$18.56	$11,154.56
2/22/2016	Richard E Kaufman	COO	Sell	3,603	$18.65	$67,195.95
1/21/2016	Richard E. Kaufman	COO	Sell	7,206	$17.93	$129,203.58
1/15/2016	Lisa D. Earnhardt	CEO	Sell	12,500	$19.26	$240,750.00
12/15/2015	Lisa D Earnhardt	CEO	Sell	6,820	$19.85	$135,377.00
11/16/2015	Lisa D Earnhardt	CEO	Sell	6,818	$18.00	$122,724.00
10/15/2015	Lisa D Earnhardt	CEO	Sell	6,818	$18.72	$127,632.96
9/15/2015	Lisa D Earnhardt	CEO	Sell	6,818	$25.99	$177,199.82
9/11/2015	Frederic H Moll	Director	Sell	10,000	$25.21	$252,100.00
8/17/2015	Lisa D Earnhardt	CEO	Sell	6,818	$28.51	$194,381.18
7/20/2015	James Stambaugh	VP	Sell	12,000	$30.52	$366,240.00
7/15/2015	Lisa D Earnhardt	CEO	Sell	19,318	$29.62	$572,199.16
6/15/2015	Lisa D Earnhardt	CEO	Sell	19,318	$29.30	$566,017.40
5/8/2015	James Stambaugh	VP	Sell	2,785	$23.87	$66,477.95
4/13/2015	Amy Wolbeck	VP	Sell	16,000	$26.25	$420,000.00
4/1/2015	James Stambaugh	VP	Sell	8,343	$25.50	$212,746.50
3/16/2015	Lisa D Earnhardt	Insider	Sell	19,318	$23.56	$455,132.08
3/11/2015	Amy Wolbeck	VP	Sell	8,000	$23.06	$184,480.00
3/9/2015	James Stambaugh	VP	Sell	8,343	$23.02	$192,055.86
2/17/2015	Lisa D Earnhardt	Insider	Sell	19,318	$22.69	$438,325.42
2/12/2015	Amy Wolbeck	VP	Sell	8,000	$22.12	$176,960.00
2/2/2015	James Stambaugh	VP	Sell	8,343	$20.98	$175,036.14
1/26/2015	Robert H Binney Jr	VP	Sell	6,300	$21.18	$133,434.00
9/11/2014	Cynthia L Lucchese	Director	Buy	5,000	$17.11	$85,550.00

(Data available from 1/1/2013 forward)

Latest Headlines for Intersect ENT (NASDAQ:XENT)

Date	Headline
	Intersect ENT, Inc. (XENT) – Broker Update - NewsDen (NASDAQ:XENT) newsden.net - September 29 at 5:50 AM
	Intersect ENT, Inc. (NASDAQ:XENT) Stock Rating Update - Investor Newswire (NASDAQ:XENT) www.investornewswire.com - September 19 at 3:15 PM
	Intersect ENT, Inc. (NASDAQ:XENT) Stock Rating Update - Investor Newswire (NASDAQ:XENT) www.investornewswire.com - September 19 at 3:15 PM
	Intersect ENT Announces American Rhinologic Society Endorsement of the Use of Drug Eluting Sinus Implants (NASDAQ:XENT) finance.yahoo.com - September 19 at 3:15 PM
	Expected For Intersect ENT, Inc. (NASDAQ:XENT) Sales Of $141.05 - Investor Newswire (NASDAQ:XENT) www.investornewswire.com - September 14 at 8:24 PM
	Intersect ENT, Inc. – Value Analysis (NASDAQ:XENT) : September 14, 2016 (NASDAQ:XENT) www.capitalcube.com - September 14 at 8:24 PM
	Intersect ENT, Inc. breached its 50 day moving average in a Bullish Manner : XENT-US : September 13, 2016 (NASDAQ:XENT) www.capitalcube.com - September 14 at 12:34 PM
	Stock Update: Estimates & Target in Focus for Intersect ENT, Inc. (NASDAQ:XENT) - Frisco Fastball (NASDAQ:XENT) friscofastball.com - September 10 at 5:46 AM
	Placing Intersect ENT, Inc. (NASDAQ:XENT) Shares Under the Microscope - Post News (NASDAQ:XENT) www.kentuckypostnews.com - September 8 at 7:47 PM
	Intersect ENT (XENT) Notes Positive CareFirst BlueCross BlueShield Coverage Determination for PROPEL - StreetInsider.com (NASDAQ:XENT) www.streetinsider.com - August 29 at 8:16 PM
	Intersect ENT Announces Positive Coverage Decision by CareFirst BlueCross BlueShield to Expand Access to PROPEL Steroid Releasing Implants to More Patients (NASDAQ:XENT) finance.yahoo.com - August 29 at 8:16 PM
	Intersect ENT Inc. (NASDAQ: XENT) Stock Rating Reiterated at ... - BNB Daily (blog) (NASDAQ:XENT) www.baseball-news-blog.com - August 29 at 5:52 AM
	Intersect ENT, Inc. (NASDAQ:XENT) Reports Sales Of $19.317, Surprising Estimates By 0.036% - Investor Newswire (NASDAQ:XENT) www.investornewswire.com - August 24 at 8:05 PM
	Will Intersect ENT, Inc. (NASDAQ:XENT) Hit $26 Price Target? - Investor Newswire (NASDAQ:XENT) www.investornewswire.com - August 22 at 5:37 AM
	What is the Sell-side Saying About Intersect ENT, Inc. (NASDAQ:XENT)? - Post News (NASDAQ:XENT) www.kentuckypostnews.com - August 18 at 8:33 PM
	Analysts See Sales Of $141.05 For Intersect ENT, Inc. (NASDAQ:XENT) - Investor Newswire (NASDAQ:XENT) www.investornewswire.com - August 18 at 11:31 AM
	INTERSECT ENT, INC. Financials (NASDAQ:XENT) finance.yahoo.com - August 16 at 8:27 PM
	ETF’s with exposure to Intersect ENT, Inc. : August 11, 2016 (NASDAQ:XENT) www.capitalcube.com - August 11 at 9:00 PM
	Intersect ENT, Inc. :XENT-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016 (NASDAQ:XENT) www.capitalcube.com - August 10 at 9:06 PM
	Newly released market study: Intersect ENT Inc. (XENT) - Medical Equipment - Deals and Alliances Profile (NASDAQ:XENT) www.live-pr.com - August 10 at 11:38 AM
	INTERSECT ENT, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:XENT) biz.yahoo.com - August 8 at 8:35 PM
	Strong Sell Calls For Intersect ENT, Inc. (NASDAQ:XENT) At 0 - Investor Newswire (NASDAQ:XENT) www.investornewswire.com - August 8 at 5:40 AM
	Intersect ENT Reports Second Quarter 2016 Results (NASDAQ:XENT) www.cbs58.com - August 3 at 11:42 AM
	Edited Transcript of XENT earnings conference call or presentation 2-Aug-16 8:30pm GMT (NASDAQ:XENT) finance.yahoo.com - August 3 at 11:42 AM
	Intersect ENT reports 2Q loss (NASDAQ:XENT) sg.finance.yahoo.com - August 2 at 8:46 PM
	Intersect ENT (XENT) Submits Supplemental PMAs for NOVA ... - StreetInsider.com (NASDAQ:XENT) www.streetinsider.com - August 2 at 5:46 AM
	Intersect ENT Announces FDA Submission of NOVA Bioabsorbable Steroid Releasing Implant for Patients With Chronic Sinus Disease (NASDAQ:XENT) finance.yahoo.com - August 1 at 8:07 PM
	Will Intersect ENT, Inc. (NASDAQ:XENT) Surprise Analysts? - Investor Newswire (NASDAQ:XENT) www.investornewswire.com - July 31 at 7:36 PM
	Is $37 Price Target Attainable For Intersect ENT, Inc. (NASDAQ:XENT)? - Investor Newswire (NASDAQ:XENT) www.investornewswire.com - July 25 at 5:49 AM
	Broker Outlook For Intersect ENT, Inc. (XENT) - Fiscal Standard (NASDAQ:XENT) www.fiscalstandard.com - July 22 at 11:17 AM
	Earnings Focus and Crowd Sourced Sentiment Review for Intersect ENT, Inc. (NASDAQ:XENT) - TGP (NASDAQ:XENT) telanaganapress.com - July 21 at 8:43 PM
	Intersect ENT, Inc. (NASDAQ:XENT) Expected To Post Sales Of $151.35 - Investor Newswire (NASDAQ:XENT) www.investornewswire.com - July 21 at 11:11 AM
	Trading Performance and Target Watch for Intersect ENT, Inc. (NASDAQ:XENT) - Press Telegraph (NASDAQ:XENT) presstelegraph.com - July 20 at 9:29 PM
	Investor Watch: Volatility Recap on Shares of: Intersect ENT, Inc. (NASDAQ:XENT) - Engelwood Daily (NASDAQ:XENT) www.engelwooddaily.com - July 20 at 9:29 PM
	Intersect ENT, Inc. (NASDAQ:XENT): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:XENT) www.engelwooddaily.com - July 20 at 9:29 PM
	Is Intersect ENT Inc. (NASDAQ: XENT) Trying To Pull A Fast One On Investors? - Scibility Media (NASDAQ:XENT) scibilitymedia.com - July 20 at 9:29 PM
	Intersect ENT Announces Preliminary Q2 Figures, Stock Up (NASDAQ:XENT) finance.yahoo.com - July 20 at 9:32 AM
	Intersect ENT (Nasdaq: $XENT) Announces Preliminary Q2 Revenue and Business Update (NASDAQ:XENT) www.investorideas.com - July 19 at 8:33 PM
	Intersect ENT Schedules Second Quarter 2016 Earnings Release and Conference Call for August 2, 2016 (NASDAQ:XENT) finance.yahoo.com - July 19 at 4:05 PM
	ETF’s with exposure to Intersect ENT, Inc. : July 19, 2016 (NASDAQ:XENT) www.capitalcube.com - July 19 at 1:25 PM
	INTERSECT ENT, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or Princip (NASDAQ:XENT) biz.yahoo.com - July 18 at 4:41 PM
	Intersect ENT, Inc. breached its 50 day moving average in a Bullish Manner : XENT-US : July 15, 2016 (NASDAQ:XENT) www.capitalcube.com - July 15 at 8:25 AM
	Intersect ENT Announces Publication of PROGRESS Study of Steroid Releasing Implant in Patients With Frontal Sinus Disease (NASDAQ:XENT) www.businesswire.com - July 12 at 10:49 AM
	Notable Tuesday Option Activity: GTLS, XENT, FEYE (NASDAQ:XENT) www.marketnewsvideo.com - June 23 at 9:09 PM
	INTERSECT ENT, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:XENT) biz.yahoo.com - June 7 at 4:10 PM
	Intersect ENT to Present at William Blair & Company 36th Annual Growth Stock Conference (NASDAQ:XENT) finance.yahoo.com - June 2 at 4:05 PM
	Intersect ENT Announces Completion of Enrollment in RESOLVE II Clinical Trial of New In-Office Implant for Recurrent Chronic Sinusitis (NASDAQ:XENT) finance.yahoo.com - June 1 at 8:00 AM
	Intersect ENT, Inc. – Value Analysis (NASDAQ:XENT) : March 10, 2016 (NASDAQ:XENT) www.capitalcube.com - March 10 at 1:20 PM
	Intersect ENT, Inc. breached its 50 day moving average in a Bearish Manner : XENT-US : March 9, 2016 (NASDAQ:XENT) www.capitalcube.com - March 9 at 8:11 AM
	INTERSECT ENT, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhib (NASDAQ:XENT) biz.yahoo.com - February 26 at 4:56 PM